PRTG Stock Overview
A clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Portage Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.26 |
| 52 Week High | US$40.80 |
| 52 Week Low | US$2.10 |
| Beta | 1.53 |
| 1 Month Change | 25.69% |
| 3 Month Change | -20.90% |
| 1 Year Change | -85.55% |
| 3 Year Change | -97.55% |
| 5 Year Change | -97.61% |
| Change since IPO | -99.21% |
Recent News & Updates
Shareholder Returns
| PRTG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | 0.7% | 0.6% |
| 1Y | -85.5% | -3.4% | 23.7% |
Return vs Industry: PRTG underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: PRTG underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| PRTG volatility | |
|---|---|
| PRTG Average Weekly Movement | 54.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRTG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRTG's weekly volatility has increased from 44% to 54% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Alex Pickett | www.portagebiotech.com |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.
Portage Biotech Inc. Fundamentals Summary
| PRTG fundamental statistics | |
|---|---|
| Market cap | US$5.90m |
| Earnings (TTM) | -US$67.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PRTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$67.28m |
| Earnings | -US$67.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -60.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRTG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 07:13 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Portage Biotech Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | B. Riley Securities, Inc. |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |